|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
Test CodeCPT Codes
86255 (x23), 86341<br>Restricted Client Code
Includes
To determine the necessity of laboratory testing for patients with suspected autoimmune encephalitis, epilepsy or dementia, see the Antibody Prevalence in Epilepsy and Encephalopathy (APE2) scorecard.
If client requests or if the immunofluorescence (IFA) patterns suggest collapsin response-mediator protein-5-IgG (CRMP-5-IgG), then the CRMP-5-IgG IFA titer and CRMP-5-IgG Western blot will be performed at an additional charge.
If the IFA patterns suggest amphiphysin antibody, then the amphiphysin IFA titer and amphiphysin immunoblot will be performed at an additional charge.
If the IFA pattern suggests antiglial nuclear antibody (AGNA)-1, then the AGNA-1 IFA titer and AGNA-1 immunoblot will be performed at an additional charge.
If the IFA pattern suggests antineuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-2 antibody, then the ANNA-2 IFA titer, ANNA-2 immunoblot, and ANNA-1 immunoblot will be performed at an additional charge.
If the client requests or the IFA pattern suggests ANNA-3 antibodies, then the ANNA-3 titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then the PCA-1 IFA titer and PCA-1 immunoblot will be performed at an additional charge.
If IFA pattern suggests PCA-Tr antibody, then the PCA-Tr IFA titer and PCA-Tr immunoblot will be performed at an additional charge.
If the IgLON5 antibody cell binding assay (CBA) result is positive, then the IgLON5 IFA titer will be performed at an additional charge.
If the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor antibody CBA result is positive, then the AMPA-receptor antibody IFA titer assay will be performed at an additional charge.
If the gamma-aminobutyric acid B (GABA-B) receptor antibody CBA result is positive, then the GABA-B-receptor antibody IFA titer assay will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then the GFAP IFA titer and GFAP CBA will be performed at an additional charge.
If the N-methyl-D-aspartate (NMDA) receptor antibody CBA is positive, then the NMDA-receptor antibody IFA titer assay will be performed at an additional charge.
If the dipeptidyl-peptidase-like protein-6 (DPPX) antibody CBA result is positive, then the DPPX IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then the mGluR1 antibody CBA and mGluR1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then the alpha internexin CBA, NIF heavy chain CBA, NIF light chain CBA, and NIF IFA titer will be performed at an additional charge.
If the IFA pattern suggests tripartite motif-containing protein 46 (TRIM46) antibody, then the TRIM46 antibody CBA and TRIM46 IFA titer will be performed at an additional charge.
If the IFA pattern suggests phosphodiesterase 10A (PDE10A) antibody, then the PDE10A antibody IFA titer will be performed at an additional charge.
84182-AGNBS (if appropriate), 86256 AGNTS (if appropriate), 86255-AINCS (if appropriate), 86256-AMPIS (if appropriate), 86256 APHTS (if appropriate), 84182-AMIBS (if appropriate), 84182-AN1BS (if appropriate), 86256 AN1TS (if appropriate), 84182-AN2BS (if appropriate), 86256 AN2TS (if appropriate), 86256 AN3TS (if appropriate), 86256 CRMTS (if appropriate), 84182-CRMWS (if appropriate), 86256-DPPTS (if appropriate), 86256-GABIS (if appropriate), 86255-GFACS (if appropriate), 86256-GFATS (if appropriate), 86256-IG5TS (if appropriate), 86255-GL1CS (if appropriate), 86256-GL1TS (if appropriate), 86255 NCDCS (if appropriate), 86256 NCDTS (if appropriate), 86255-NFHCS (if appropriate), 86256-NIFTS (if appropriate), 86255-NFLCS (if appropriate), 86256-NMDIS (if appropriate), 84182-PC1BS (if appropriate), 86256 PC1TS (if appropriate), 86256 PC2TS (if appropriate), 84182-PCTBS (if appropriate), 86256 PCTTS (if appropriate), 86256 PDETCS (if appropriate), 86255 SP7CS (if appropriate), 86256 SP7TS (if appropriate), 86255 T46CS (if appropriate), 86256 T46TS (if appropriate)
Preferred Specimen
Patient Preparation
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
2. This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Minimum Volume
Instructions
Transport Temperature
Specimen Stability
Refrigerated: 28 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Immunoblot • Indirect Immunofluorescence Assay • Radioimmunoassay • Western Blot
Setup Schedule
Reference Range

